- 1 Title: Detecting Glaucoma Worsening Using Optical Coherence Tomography Derived
- 2 Visual Field Estimates
- 3 Authors: Alex T. Pham<sup>1</sup>, Chris Bradley<sup>1</sup>, Kaihua Hou<sup>2</sup>, Patrick Herbert<sup>2</sup>, Mathias
- 4 Unberath, Pradeep Y. Ramulu<sup>1</sup>, Jithin Yohannan<sup>1,2</sup>
- <sup>5</sup> <sup>1</sup>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD,
- 6 USA.
- <sup>7</sup><sup>2</sup>Malone Center for Engineering in Healthcare, Johns Hopkins University, Baltimore,
- 8 Maryland
- 9 Corresponding author: Jithin Yohannan, MD MPH
- 10 Wilmer Eye Institute, Johns Hopkins Hospital
- 11 600 N. Wolfe St., Baltimore, MD 21287, USA
- 12 jithin@jhmi.edu
- 13 **Meeting Presentation:** Association for Research in Vision and Ophthalmology (ARVO)
- 14 2023
- 15 **Financial Support:** Supported by grants from the National Institute of Health
- 16 1K23EY032204-02, Research to Prevent Blindness Unrestricted Grant, BrightFocus
- 17 Foundation G2023010S, and ARVO Epstein Award
- 18 **Conflict of Interest:** None relevant

- 19 **Running head:** Detecting glaucoma progression with OCT-derived VF estimates
- 20 Reprint Address: Wilmer Eye Institute, Johns Hopkins Hospital, 600 N. Wolfe St.,
- 21 Baltimore, MD 21287, USA.

#### 22 Abstract

- 23 **Objective:** Multiple studies have attempted to generate visual field (VF) mean deviation
- 24 (MD) estimates using cross-sectional optical coherence tomography (OCT) data.
- 25 However, whether such models offer any value in detecting longitudinal VF progression
- is unclear. We address this by developing a machine learning (ML) model to convert
- 27 OCT data to MD and assessing its ability to detect longitudinal worsening.
- 28 **Design:** Retrospective, longitudinal study
- 29 **Participants:** A model dataset of 70,575 paired OCT/VFs to train an ML model
- 30 converting OCT to VF-MD. A separate progression dataset of 4,044 eyes with  $\geq$  5
- 31 paired OCT/VFs to assess the ability of OCT-derived MD to detect worsening.
- 32 Progression dataset eyes had two additional unpaired VFs (≥ 7 total) to establish a
- 33 "ground truth" rate of progression defined by MD slope.

34 Methods: We trained an ML model using paired VF/OCT data to estimate MD 35 measurements for each OCT scan (OCT-MD). We used this ML model to generate 36 longitudinal OCT-MD estimates for progression dataset eyes. We calculated MD slopes 37 after substituting/supplementing VF-MD with OCT-MD and measured the ability to 38 detect progression. We labeled true progressors using a ground truth MD slope < 0.539 dB/year calculated from  $\geq$  7 VF-MD measurements. We compared the area under the 40 curve (AUC) of MD slopes calculated using both VF-MD (with <7 measurements) and 41 OCT-MD. Because we found OCT-MD substitution had a statistically inferior AUC to 42 VF-MD, we simulated the effect of reducing OCT-MD mean absolute error (MAE) on the 43 ability to detect worsening.

# 44 Main Outcome Measures: AUC

45	Results: OCT-MD estimates had an MAE of 1.62 dB. AUC of MD slopes with partial
46	OCT-MD substitution was significantly worse than the VF-MD slope. Supplementing VF-
47	MD with OCT-MD also did not improve AUC, regardless of MAE. OCT-MD estimates
48	needed an MAE $\leq$ 1.00 dB before AUC was statistically similar to VF-MD alone.
49	Conclusion: ML models converting OCT data to VF-MD with error levels lower than
50	published in prior work (MAE: 1.62 dB) were inferior to VF-MD data for detecting trend-
51	based VF progression. Models converting OCT data to VF-MD must achieve better
52	prediction errors (MAE $\leq$ 1 dB) to be clinically valuable at detecting VF worsening.
53	Keywords: mean deviation, estimate, optical coherence tomography, visual field
54	Abbreviations and Acronyms: VF, visual field; MD, mean deviation; dB, decibels;
55	OCT, optical coherence tomography; RNFL, retinal nerve fiber layer; ML, machine
56	learning; MAE, mean absolute error; SVM, support vector machine; AUC, area under
57	the curve

58

## 59 Introduction

Early detection of glaucoma progression is critical to manage the disease effectively. 60 61 Identifying those at the highest risk of progression allows clinicians to adjust therapy 62 before additional irreversible vision loss occurs. Glaucoma monitoring is usually done by 63 tracking structural changes with optical coherence tomography (OCT) imaging and 64 functional changes with visual field (VF) testing. Since OCT imaging and VF testing 65 have their respective advantages and disadvantages that make either alone less than 66 ideal for detecting progression, they are often used in combination. In general, there are 67 differences in the ability of VF and OCT to detect glaucoma worsening at various stages 68 of the disease. OCT is more sensitive to detecting disease progression in earlier stages 69 of glaucoma. At the same time, VF is more informative at later stages when structural 70 features reach the measurement floor of the OCT instrument.<sup>1–7</sup> 71 There are multiple approaches to addressing the difference between OCT and VF to 72 monitor progression. While clinicians are skilled at monitoring progression using their 73 own experience and judgment, it has been suggested that OCT could help guide VF 74 testing by focusing on measuring functional changes in regions with significant 75 structural changes as the structure-function relationship demonstrates better agreement 76 with regional or sectoral measurements.<sup>8</sup> Another approach involves using structural 77 information from OCT, such as the retinal nerve fiber layer (RNFL), to predict functional 78 measures, such as mean deviation (MD).<sup>9–16</sup> The appeal of this pursuit is that it relates 79 different measurement scales (microns per year versus dB per year), and it provides a

80 "functional" measure while retaining the inherent clinical advantages of OCT, such as

better repeatability, reproducibility, objectivity, and sensitivity to early glaucomatous
damage.<sup>3-5,17-20</sup>

83 Due to the growing availability of large datasets from electronic health records, most 84 recent efforts to predict MD from OCT (OCT-MD) have focused on applying deep 85 learning models to optic nerve head OCT scans, macular OCT scans, or both.<sup>9–14,16</sup> 86 However, the OCT-MD estimations from these models have limited accuracy, with 87 mean absolute errors (MAE) ranging from 2-5 dB <sup>9–14,16</sup>The test-retest variability of MD measurements from VF (VF-MD) is less than 1.5 dB.<sup>21,22</sup> The best-performing structure-88 89 function models in the work mentioned above report MAEs of approximately 2 dB. It is 90 likely that OCT-MD alone cannot predict progression with the same accuracy as VF, but 91 this has yet to be assessed. Additionally, OCT-MD estimates could still have clinical 92 utility if assessed in combination with VF measurements. This is relevant because 93 patients often alternate between OCT and VF and frequently have both available for the 94 clinician to assess progression. Assuming at least five VFs are needed to calculate a 95 reliable MD rate of change for monitoring trend-based progression, the ability to 96 substitute VF-MD with OCT-MD would reduce the testing burden on patients and allow 97 clinicians to determine the rate of change more guickly, leading to earlier detection of 98 progression.<sup>23,24</sup> This is especially important since treatment decisions must often be 99 made only after a few visits.

Hence, the aims of our study are two-fold. First, our study aimed to evaluate whether
OCT-MD has any clinical value as a substitute for VF-MD (either through complete or
partial substitution) to detect trend-based glaucoma progression with non-inferior
accuracy to VF-MD alone. Second, if we find that OCT-MD estimates, with an MAE

similar to or better than prior published work, are not accurate enough to be clinically

- 105 viable, we aimed to determine the MAE needed for OCT-MD to be useful in trend-based
- 106 analysis. Currently, there is no established evidence-based MAE threshold that
- 107 investigators developing these models should aim to stay below. Thus, knowing the
- 108 maximum acceptable error level would clarify the ideal goal for modeling the structure-
- 109 function relationship to detect functional change over time.

#### 110 Methods

- 111 Our study adhered to the Declaration of Helsinki and was approved by the Johns
- 112 Hopkins University School of Medicine Institutional Review Board.

#### 113 Study Population and Data Collection

114 Adult patients with a glaucoma or glaucoma-related diagnosis followed at the Wilmer 115 Eye Institute Glaucoma Center of Excellence from April 2013 to July 2022 were 116 considered eligible for our study. From these eligible eyes, we created a dataset to train 117 and test a machine learning model to estimate OCT-MD, referred to as the "model 118 dataset", and a separate dataset to evaluate the ability to predict VF worsening from 119 trend-based analysis of the OCT-MD generated by the model, referred to as the 120 "progression dataset". The same eye or patient was never present in both datasets. For 121 the progression dataset, the inclusion criteria were eyes with 5 or more reliable VFs 122 (reliability criteria defined below), each paired with a reliable optic nerve head OCT scan 123 (reliability criteria defined below) taken within a 1-year time window. Each pairing was 124 unique in that there were no overlapping VFs or OCTs among the pairings. These eyes 125 also had to have 2 additional unpaired VF tests. The rationale for these inclusion criteria 126 was based on the notion that at least 5 VF tests are needed to calculate a reliable MD 127 slope<sup>23,24</sup>, and the additional 2 unpaired VF tests were used to establish a ground truth 128 for the rate of progression. Hence, each eye in the progression dataset had 7 or more 129 VFs. For the model dataset, the inclusion criteria were peripapillary OCT scans and VF 130 tests obtained from eyes with less than 7 VFs over time, so there are no overlapping 131 eyes between the progression and model dataset. OCT scans and VF tests also had to 132 be paired within one year of each other. Only reliable OCT scans and reliable VF tests were considered during the construction of the model dataset as well. 133

134 For OCT scans to be considered reliable, they had to have a signal strength > 6, and 135 average, superior quadrant, and inferior quadrant RNFL thickness measurements 136 between 57 to 135, 175, and 190 µm, respectively. An RNFL floor of 57 µm was used 137 because values below this threshold are likely due to artifact or segmentation error.<sup>25,26</sup> 138 Moreover, it is unlikely any further longitudinal changes can be observed in eyes that 139 have reached the OCT floor.<sup>27</sup> An RNFL ceiling of 135, 175, and 190 µm was used for 140 the average, superior, and inferior thickness, respectively, because these thresholds are 141 approximately three standard deviations above the average RNFL thickness measured 142 in normal healthy eyes.<sup>28</sup> All OCT studies were obtained using CIRRUS HD-OCT 143 (Zeiss, Dublin, CA).

To be considered reliable, VFs had to have false positive rates < 15% for all stages of</li>
disease, false negative rates < 25% for suspect or mild glaucoma, and false negative</li>
rates < 50% for advanced glaucoma.<sup>29</sup> All VF tests were performed using the Humphrey
Visual Field Analyzer II or III with the SITA Standard, Fast, or Faster testing algorithm
and the 24-2 pattern. Only VF tests with MD measurements better than –10.4 dB were

149 included in the study because MDs worse than -10.4 dB likely indicate that the eye has 150 reached the RNFL floor.<sup>27</sup> Since our study aims to assess the feasibility of detecting 151 progression with OCT-derived MD, the rationale for this restriction is to provide the most 152 favorable conditions that would produce the most accurate conversion estimates. If the 153 progression cannot be accurately detected using estimates limited to the dynamic range 154 of OCT, it is unlikely to have the potential for clinical utility in real-world circumstances. 155 Variables collected for our study included age, gender, race, and glaucoma severity. 156 Glaucoma severity was determined using the MD measurement from the first VF 157 available for each eye. Eyes with a baseline MD better than -6 dB and between -6 and 158 -10.4 dB were considered suspect/mild and moderate glaucoma, respectively. Eyes with an MD better than -6 dB were considered glaucoma suspect, as opposed to mild 159 160 glaucoma, if their glaucoma hemifield test was "within normal limits". 161 Estimating VF Mean Deviation from Optic Nerve OCT Characteristics in the Model 162 Dataset 163 Using the model dataset, we investigated multiple machine-learning models to estimate 164 MD based on various features measured by OCT scans of the optic disc. Input features

165 for each model were the average RNFL thickness, four quadrant RNFL thicknesses

166 (superior, inferior, nasal, temporal), 12 clock hour RNFL thicknesses, 6 Garway-Heath

167 Zone RNFL thicknesses, cup volume, disc area, rim area, average cup-to-disc ratio,

168 vertical cup-to-disc ratio, signal strength, and baseline age. Classical machine learning

algorithms that were tested included random forest, support vector machine (SVM)

170 regression, lasso regression, and K-nearest neighbors. We also tested deep learning

171 models such as convolutional neural networks, multi-layer perceptron, and a model

172 combining both previous neural networks. A training and testing set were created using 173 an 80:20 percent split of the model dataset described above. Hyperparameters were 174 optimized by comparing the performance of various combinations of parameters after 175 cross-validation on the training set. We used 5-fold cross-validation, which involves 176 randomly splitting the training set into five non-overlapping folds of equal size. The 177 model was then trained on a combination of four folds while the remaining fold, a 178 holdout set, was used for validation to evaluate performance. An evaluation score was 179 obtained from this holdout set, and this process was repeated five times so that each 180 fold had an opportunity to be used once for validation. The model's performance for a 181 particular combination of hyperparameters was then summarized by taking the average 182 of the evaluation scores from the five iterations. The combination of parameters that 183 produced the strongest average evaluation score after cross-validation was used as the 184 optimal parameters for the model. Afterward, the performance of each optimized model 185 was evaluated by generating an OCT-MD from each paired OCT scan in the test set 186 and calculating the mean absolute error (MAE) between the OCT-MD estimate and the 187 real MD measurement, VF-MD. The optimized model with the lowest MAE obtained 188 from the test set was used to predict disease progression described in the following 189 section.

#### 190 Detecting Glaucoma Progression in the Progression Dataset

An overview of our study method can be seen in Figure 1. After constructing a model to generate OCT-MD, an MD estimate was obtained from each paired OCT scan for each eye in the progression dataset. We evaluated the utility of using these OCT-MD estimates with VF-MD to detect trend-based glaucoma progression. Our primary

195 approach involved selecting a random subset of the longitudinal VF-MD measurements, 196 replacing them with their paired OCT-MD estimates, and calculating the MD slope using 197 ordinary least squares regression. We refer to this approach of combining OCT-MD and 198 VF-MD as 'substitution'. The MD slope calculation from substitution is referred to as the 199 'VF-MD/OCT-MD slope'. Varying amounts of VF-MD substitutions were tested: 20%, 200 40%, 60%, 80%, and 100% substitution. For example, if an eye had ten VF studies with 201 ten paired OCT scans, 80% substitution means that randomly chosen eight VF-MDs 202 were replaced with their paired OCT-MDs.

203 We were also interested in investigating whether OCT-MD could be used to improve the

204 predictive ability of VF-MD when it is included as supplemental information in trend-

205 based analysis. In other words, our secondary approach involved combining all OCT-

206 MD estimates with all paired VF-MD measurements by using OCT-MD as additional

207 data points in the MD slope calculation with ordinary least squares regression. We refer

to this approach of combining OCT-MD and VF-MD as 'addition'. The MD slope

209 calculation from addition is referred to as the 'VF-MD + OCT-MD slope'.

210 To evaluate the accuracy of the VF-MD/OCT-MD slopes and VF-MD + OCT-MD slopes, 211 we established a "ground truth" MD slope for analysis purposes. The ground truth MD 212 slope was calculated using all available VF studies (at least 7 or more), which equate to 213 two additional data points beyond the time window of the paired VF tests and OCT 214 scans (at least 5 or more) for each eye in the progression dataset. Receiver operating 215 characteristic curves were generated for VF-MD/OCT-MD slopes and VF-MD + OCT-216 MD slopes using the ground truth MD slope. Eyes with a statistically significant ground truth MD slope ( $\alpha = 0.05$ ) worse than -0.50 dB/year were labeled true progressors.<sup>30-33</sup> 217

218 We also repeated the analysis to determine whether OCT-MD could predict slower and

- faster rates of VF worsening by using MD slope cut-offs of -0.25, -0.75, and -1.00
- 220 dB/year. The area under the receiver operating characteristic curve (AUC) was used to
- evaluate the performance of the VF-MD/OCT-MD and VF-MD + OCT-MD slopes.
- 222 To compare the VF-MD/OCT-MD slopes derived from substitution to VF-MD, we
- 223 calculated an MD slope when no VF-MDs were substituted, which we will refer to as the
- baseline VF-MD slope. The VF-MD/OCT-MD slopes for 20%, 40%, and 60%
- substitution were also compared to baseline VF-MD slopes calculated using 20%, 40%,
- and 60% fewer VFs to determine whether partial substitution with OCT-MD does better
- than simply using fewer VFs to calculate MD slope. Statistical comparisons between the
- AUCs of the MD slopes were made using Delong's test.
- 229 Accuracy Needed to Predict Progression with OCT- MD

230 After evaluating the performance of VF-MD/OCT-MD and VF-MD + OCT-MD slopes in 231 predicting progression, we investigated the impact of OCT-MD MAE on the AUCs. It is 232 currently unknown what MAE is needed for OCT-MD estimates to be viable when used 233 alone or combined with VF-MD in trend-based analysis to detect progression. To 234 simulate OCT-MD model estimates with a lower MAE, we took the original MAE of our 235 model and calculated the error percent reduction needed to lower it to 1.50, 1.25, 1.00, 236 0.75, and 0.50 dB. Then, we calculated the residual error between the paired OCT-MD 237 and VF-MD for the eyes in our progression dataset. The OCT-MD estimates were 238 brought closer to the paired VF-MD measurements by artificially reducing the residual 239 error between them by the percentages calculated above. As an example, if the original 240 MAE of our model was 2.00 dB, the percent reduction needed to achieve an MAE of

1.50 dB would be 25%. If the original OCT-MD estimate was -2.00 dB and the paired
VF-MD was -1.00 dB, the residual error would be 1.00 dB. A 25% reduction of the
residual would lead to a simulated OCT-MD estimate of -1.75 dB. MD slopes were
recalculated using these simulated OCT-MD estimates, and the AUC analysis was
repeated.

#### 246 Sensitivity Analyses

247 We conducted two sensitivity analyses. First, since our current inclusion criteria allow 248 OCT scans and VFs to be paired up to one year apart, this may introduce temporal bias 249 in the model. The OCT-MD produced by the model could be estimating a VF-MD one 250 year ahead or behind the OCT scan date, which may affect our analysis of longitudinal changes to predict progression. To address this concern, we conducted a sensitivity 251 252 analysis by training our machine learning model on only OCT scans and VF tests that 253 were paired on the same day. In addition, when using the OCT-MD estimates to detect 254 glaucoma progression, we only analyzed eyes with 5 or more OCT scans and VF tests 255 also paired on the same day. Second, we investigated including confidence intervals 256 when labeling true progressors since OCT-MD may not be able to detect progression in 257 those with nosier VF tests. The confidence interval for a statistically significant MD slope 258 had to be within a 0.50 dB range (+/- 0.25 dB of the slope) to be considered as a true 259 progressor.

## 260 Results

Baseline demographics, VF, and OCT characteristics for the model and progression
datasets are shown in Table 1. The model dataset consisted of 70,575 paired optic disc

263 OCT scans and VF studies obtained from 44,659 eyes, each with less than 7 reliable 264 VFs. The progression dataset consisted of 4,044 eyes with at least 7 reliable VFs, with 265 all but the last 2 VFs paired with OCT. The mean (SD) duration of time between OCT 266 scans and VF studies for each pair was 102 (117) days. The mean age was slightly 267 older in the progression dataset than in the model dataset (64 vs. 62 years, p < 0.001). 268 Race, gender, and baseline glaucoma severity were similar for both datasets. Mean MD 269 was slightly worse in the model dataset than in the progression dataset (-1.86 vs. -1.59)270 dB, p < 0.001). Pattern standard deviation was slightly better in the model dataset than 271 in the progression dataset (2.46 vs. 2.56, p = 0.001). RNFL was slightly thinner (83 vs. 272 86  $\mu$ m, p < 0.001) and CDR slightly larger (0.62 vs. 0.60, p < 0.001) in the progression 273 dataset than the model dataset.

274 Among the different machine learning models evaluated, the SVM model had the lowest 275 MAE and was used for the remainder of the study. Table 2 shows the MAE of the SVM 276 model and the percentage of OCT-MD estimates within 0.25 dB, 0.50 dB, 1.00 dB, 2.00 277 dB, and 4.00 dB of the true MD value. Overall, the MAE was 1.62 dB, and the 278 percentage of estimates with 0.25 dB, 0.5 dB, 1 dB, 2 dB, and 4 dB of error were 11%, 279 21%, 41%, 71%, and 93%, respectively. The estimations became more inaccurate for 280 later stages of disease. The estimates from eves with suspect and mild glaucoma had 281 an MAE below 2 dB and the highest proportion of estimates within the various margins 282 of error. Estimates from eyes with moderate disease had the worst MAE of 5.55 dB and 283 the lowest proportions within the various margins of error. This trend is also seen in 284 Figure 2, demonstrating that the MAE of OCT-MD estimates increases the further VF-285 MD is from -1.0 dB.

286 Ability of MD slope to detect progression when combining VF-MD with OCT-MD

287 Figure 3 demonstrates the diagnostic ability of VF-MD/OCT-MD slopes (substitution) 288 calculated from various substitution percentages. For an MD slope cutoff of 0.50 289 dB/year, the AUCs (95% CI) for 20%, 40%, 60%, 80%, and 100% substitution are 0.88 290 (0.86 to 0.90), 0.84 (0.81 to 0.86), 0.77 (0.74 to 0.80), 0.70 (0.67 to 0.74), and 0.60 291 (0.58 to 0.64), respectively. The AUC (95% CI) of the baseline VF-MD slope is 0.91 292 (0.90 to 0.93) and corresponds to 0% substitution. The AUC of the baseline VF-MD 293 slopes calculated using 20%, 40%, and 60% fewer VFs is 0.90 (0.88 to 0.92), 0.86 (0.83 294 to 0.88), and 0.77 (0.73 to 0.80). The AUC of 40% to 100% substitution was significantly 295 worse than the baseline VF-MD slope. Although the AUC of 20% substitution was 296 statistically similar to the baseline VF-MD slope with 0% substitution, it was also similar 297 to the AUC of baseline VF-MD slopes calculated using 20% fewer VFs. The AUC of the 298 OCT-MD slope from 40% and 60% substitution was similar to the baseline VF-MD slope 299 calculated using 40% and 60% fewer VFs, respectively, as well. Figure 3 also shows 300 the AUCs for substitution when using faster and slower MD slope cut-offs. The number 301 of progressing eyes using an MD slope cutoff of -0.25, -0.50, -0.75, and -1.00 dB/year were 380, 149, 47, and 19 eyes, respectively. 302

Table 3 shows the AUCs of the VF-MD + OCT-MD slope (addition) compared to the
baseline VF-MD slope for various MD slope cutoff thresholds. For an MD slope cutoff of
0.50 dB/year, the AUC when using OCT-MD as additional data points is 0.89 (0.87 to
0.91) and was statistically similar to the baseline VF-MD slope. VF-MD + OCT-MD
slopes were also statistically similar to the baseline VF-MD slope for slower and faster
MD-slope cutoffs.

### 309 Accuracy Simulation

310 The diagnostic ability of VF-MD/OCT-MD slopes with an MAE of 1.50, 1.25, 1.00, 0.75, 311 and 0.50 dB is shown in Figure 4. Figure 4 demonstrates that an MAE of 1.25 dB or 312 better is needed for the AUCs of VF-MD/OCT-MD slopes to be above 0.80 for complete 313 and partial substitution. When the MAE was 1.00 dB or better, the performance became 314 nearly identical to VF-MD alone. For an MAE of 1.25 dB or better, 40% substitution had 315 a higher AUC than simply using 40% fewer VFs. On the other hand, the AUC for 60% 316 substitution only became higher than simply using 60% fewer VFs when the MAE was 317 1.50 dB or better. 318 We performed a similar error simulation to evaluate the diagnostic ability of VF-MD + 319 OCT-MD slopes calculated using OCT-MD estimates with an MAE of 1.50, 1.25, 1.00, 320 0.75, and 0.50 dB. We found that regardless of the accuracy of OCT-MD estimates,

321 using OCT-MD as additional data points for MD slope calculation did not improve the

322 AUC compared to using VF-MD alone.

## 323 Sensitivity Analyses

In our first sensitivity analysis, we repeated the main analysis using only VF studies and OCT scans performed on the same day to address possible temporal bias introduced when estimating VFs from OCTs paired up to one year apart. The structure-function model had minimal improvement in performance, with an MAE of 1.59 dB for the OCT-MD estimates compared to an MAE of 1.62 dB for the OCT-MD estimates from the original model. We also achieved similar results to our original analysis when examining the predictive ability of the OCT-MD estimates to predict glaucoma progression.

However, it is important to note that the sample size for the progression dataset was substantially smaller with the adjusted inclusion criteria compared to the original inclusion criteria (n = 562 vs. n = 4,044).

334 In our second sensitivity analysis, we repeated the main analysis but required 335 progressing eyes to have an MD slope worse than 0.50 dB/year, p-value < 0.05, and 336 confidence intervals to be within +/- 0.25 dB of the calculated slope. Among the 4,044 337 eyes in the progression dataset, 19 were considered progressing using the above 338 criteria. Similar trends were seen. The AUCs of partially substituted VF-MD/OCT-MD 339 slopes were lower than the baseline VF-MD slope and were worse with increasing 340 substitution percentages. VF-MD/OCT-MD slopes with 20% substitution had a similar 341 AUC to the baseline VF-MD slope, but the same was true for VF-MD slopes using 20% 342 fewer VFs. The AUCs of the VF-MD + OCT-MD slope were similar to the baseline VF-343 MD slope.

Discussion

344

345 In this study, we developed a machine learning model trained on optic nerve head OCT 346 measurements to estimate MD with an error (MAE) of 1.62 dB. The error of the OCT-347 MD estimates increased with increasing disease severity. Completely substituting VF-348 MD with OCT-MD resulted in significantly lower AUCs compared to using VF-MD alone. 349 Partially substituting only 20% of VF-MD with OCT-MD had a statistically similar AUC 350 compared to using VF-MD alone. However, partial substitution did not perform better 351 than simply using 20% fewer VFs. Using OCT-MD as additional data points with VF-MD 352 for MD slope calculation did not improve the AUC regardless of the MAE. OCT-MD

353 estimates predicted progression as well as VF-MD alone when the MAE was at or

354 below 1.00 dB.

355 Model Performance for Estimating Mean Deviation

356 When predicting VF-MD from OCT data, our structure-function SVM model achieved an 357 overall MAE of 1.62 dB. Prior classical machine-learning and deep-learning models 358 were also trained with structured data, such as thickness measurements, and had mean 359 errors ranging from 3 - 5 dB.<sup>12,34,35</sup> Our MAE also compares well to more recent studies 360 with sophisticated deep learning models incorporating unstructured data from 361 unsegmented OCT images, which contain much more information than tabular RNFL thickness measurements (MAE ranging from 2.3 – 2.8 dB).<sup>11,36,37</sup> Our findings are also 362 363 consistent with those of Wong et al. (2022), who compared different machine learning 364 models trained on global RNFL thickness measurements to estimate global VF-MD and 365 found that gradient-boosted decision trees and SVM performed significantly better than 366 other models, including some deep learning models.<sup>35</sup>

367 Several reasons may explain the better MAE observed in our study compared to 368 previous work. Our structure-function model was trained on a substantially larger 369 dataset (more than 50,000 OCT-VF pairs). It was trained on additional optic nerve 370 features such as cup volume, disc area, rim area, and cup-to-disc ratio, not just RNFL 371 thickness measurements. Unlike previous studies, we limited OCT-VF pairs used to 372 train the model to only those that fall within the dynamic range of the OCT imaging 373 instrument. The poor accuracy and variability of OCT-MD estimates as visual function 374 worsens is well documented, and the reduced dynamic range of RNFL thicknesses in later stages of glaucoma is a frequently cited reason.<sup>15,34,38</sup> Moreover, limiting our study 375

population to the dynamic range also limits the generalizability of our model. The model
was trained on mostly suspect or mild glaucoma, as eyes with more advanced disease
would likely fall outside of the dynamic range. The VF measurements from more
advanced diseases are known to be much more variable, which could explain the higher
MAEs observed in prior studies.<sup>9–14,16,39</sup>

381 Since our study aimed to evaluate the feasibility of utilizing OCT-MD in trend-based 382 analysis, we decided to use the conditions that would provide the most accurate 383 estimations. Although this means the generalizability of our findings is likely limited to 384 eyes with earlier stages of glaucoma, it is unlikely that including eyes outside the 385 dynamic range, such as those with moderate or advanced glaucoma, would change the 386 main findings of our study. If it is not possible to use OCT-MD to improve the ability to 387 detect progression in eyes with earlier stages of disease, it is unlikely that OCT-MD 388 would be helpful in eves with later stages of disease where OCT-MD estimations would 389 be even more inaccurate and variable.<sup>39</sup>

390 Detecting Glaucoma Progression with OCT Estimated Mean Deviation

391 Combining OCT-MD with VF-MD, either through substitution or addition, did not 392 significantly improve the ability to detect progression. Completely or partially substituting 393 VF-MD with OCT-MD led to a worse ability to detect progression than using VF-MD 394 alone. Although only substituting 20% of VF-MD led to statistically similar predictions 395 compared to VF-MD alone (AUC of 0.86 vs 0.87), the same could be achieved by 396 simply using 20% fewer VFs when calculating the rate of MD worsening. When using 397 OCT-MD as additional data points to calculate the rate of MD worsening, the AUC was 398 statistically similar to VF-MD alone, regardless of the MAE. However, when MAE was

1.00 dB or better, the OCT-MD estimates could be considered for substitution as theperformance was similar to VF-MD alone.

401 If a low enough MAE could be achieved, there are multiple potential advantages to 402 being able to convert an RNFL measurement to MD that we could expect. Since 403 patients often alternate between OCT imaging and VF testing, one may detect 404 glaucoma progression earlier since less time is needed to estimate the rate of MD 405 worsening by using both OCT-MD and VF-MD. Being able to substitute VF-MD with 406 OCT-MD in these situations offers great flexibility in the amount and type of testing 407 needed to produce accurate trend assessments. Due to the variability of VF testing, 408 especially for later stages of disease, at least 10 VFs are required to obtain the most 409 accurate progression rate estimate.<sup>40</sup> Adding OCT-MD as additional data points with 410 VF-MD in these trend-based analyses may also allow one to obtain more accurate 411 progression rate estimates in less time.

412 Despite the numerous efforts directed at developing structure-function models, there is 413 currently no established evidence-based accuracy threshold that investigators can use 414 to validate the clinical utility of their models. Our work demonstrates that OCT-MD 415 estimates with margins of error greater than 1.00 dB did not provide clinical value in 416 detecting glaucoma progression using trend-based analysis, even when combined with 417 VF-MD measurements through partial substitution or addition. Figure 2 demonstrates 418 that only when OCT-MD is used to predict VF-MD measurements within a 0 to -2 dB 419 range the MAE could be better than 1.00 dB. For most clinical situations, detecting VF 420 worsening within such a narrow range would be challenging. In a best-case scenario, 421 current OCT-MD estimates may help detect worsening in pre-perimetric glaucoma.

422 More work is needed to produce OCT-MD estimates that are accurate enough to 423 estimate progression rates. Several improvements can be made to our model to 424 achieve the required accuracy. We only used mainly RNFL thickness measurements to 425 predict MD, but more accurate estimations may be achieved if we develop a deep 426 learning model that utilizes the RNFL thickness measurements and the corresponding 427 raw, unsegmented OCT image. Lazaridis et al. (2022) previously demonstrated that an 428 ensemble model utilizing the OCT image and the RNFL thickness profile had 429 approximately a 22% lower MAE than a model using only the RNFL thickness profile.<sup>37</sup> They suggested that OCT images contain additional information, such as vascular 430 431 features that may be relevant to the structure-function relationship, as retinal ganglion 432 cell loss in glaucomatous eyes with VF damage is associated with decreased regional 433 retinal blood flow.<sup>41,42</sup> Indeed, some studies have found that combining vasculature 434 measurements from OCT angiography with structural OCT measurements can improve 435 the ability to assess VF defects.<sup>43,44</sup> Another important structural feature that can 436 improve prediction accuracy is macular information. Yu et al. (2021) found that a deep 437 learning model using both macular and optic nerve head scans had a lower median absolute error for predicting MD than either alone.<sup>36</sup> Studies suggest that macular OCT 438 439 also has a larger dynamic range than optic nerve head OCTs and may be more useful 440 in predicting visual function in the later stages of glaucoma which can potentially help 441 address the poor accuracy observed with structure-function models in later stages of disease and improve generalizability.<sup>45–47</sup> Additionally, macular changes can be seen in 442 443 early glaucoma, and incorporating this information could also further improve the 444 estimations at earlier stages of disease. 48-50,50-54

445 Another approach to detecting glaucoma progression using structure-function models 446 that we did not investigate is predicting pointwise VF measurements. In addition to 447 global VF indices, there are efforts to use OCT to estimate individual pointwise VF sensitivities.<sup>10–12,15,34,37,55</sup> Predicting threshold sensitivities would maintain the spatial 448 449 relationships between structural features that would not be reflected in an estimated 450 summary metric such as MD. These spatial relationships may help in the early detection 451 of localized disease progression before they can affect the global VF metrics. However, 452 predicting pointwise measurements is a significantly more complex task than predicting 453 global measurements.

454 Since the ultimate goal is to detect disease progression, other approaches that are 455 important to continue investigating are models that predict progression directly rather 456 than computing a VF metric from an OCT metric and then performing a subsequent 457 analysis to predict disease progression. Models utilizing this approach have achieved 458 good performance (AUC > 0.80) in predicting VF worsening from longitudinal OCT 459 information.<sup>33,56–58</sup> In our previous study, we used a gated-transformer network to 460 predict VF worsening based on MD slope with longitudinal OCT scans.<sup>33</sup> An advantage 461 of this approach is that we could detect spatially dependent structural changes over 462 time with our deep learning model, unlike this study. However, the model is limited by 463 the fact that it requires a minimum of 5 OCT scans as an input (a disadvantage that is 464 not present with the conversion approach). While waiting for enough tests, patients may 465 experience additional vision loss or be lost to follow-up. Consequently, treatment 466 decisions are often needed after only a few visits. These drawbacks also highlight the

467 importance of models identifying future disease worsening with an early or limited
468 diagnostic dataset.<sup>58</sup>

469 There are important limitations to acknowledge in our study. Although our SVM model 470 achieved a low MAE, we only used tabular data from segmented RNFL measurements. 471 As mentioned earlier, it is possible that if we incorporated the unsegmented OCT 472 images, macular OCTs, or OCT angiography into a deep-learning model, we could 473 achieve better MD estimates. We only investigated glaucoma worsening through MD 474 slope but other trend-based analyses such as VFI slope may produce different results. 475 Global VF indices also cannot show spatial relationships, and there is growing evidence 476 that regional or sectoral changes demonstrate better agreement between structure and 477 function.<sup>8</sup> Predicting pointwise threshold sensitivities rather than global indices may be 478 more useful for evaluating progression in other situations, such as with event-based 479 analysis. When conducting our error simulations, we artificially reduced the residual for 480 each estimate by a certain percentage to mimic a structure-function model with better 481 accuracy, but this assumes that improvements can be made to the model that would 482 improve the accuracy universally among all eyes with differing baseline characteristics 483 and reduce error across all levels of VF damage in the same proportions. Additionally, 484 our structure-function model is trained to predict a single paired VF taken at a single 485 clinic visit and this assumes that the single VF is a true representation of the eye's 486 visual function. However, VF measurements are variable, especially at later stages of 487 disease, and the error observed with the OCT-MD estimates for given measurement will 488 be partly due to this inherent variability. Another approach could involve predicting an 489 average of multiple VF tests as the 'best available estimate' of the true visual function.<sup>37</sup>

490 However, it would be impractical to obtain multiple VF measurements for each patient 491 on a single visit and do so on a large scale to train a model. The VF studies included 492 are obtained from a mix of testing strategies, and this could potentially confound the MD 493 measurements, but this may only be a limitation for later stages of glaucoma. Prior 494 studies have shown that SITA Faster and SITA Standard perform similarly in mild 495 disease, and performance differences are more pronounced in later stages of 496 disease.<sup>59–63</sup> As the majority of our eyes are suspect or mild glaucoma (93%), we have 497 less concern for measurement bias. Lastly, VF and OCT were paired within one year and this assumes no glaucomatous changes occurred during this timeframe. Although 498 499 Chauhan et al. (2014) have shown that most eyes have slow rates of VF progression. It 500 is unlikely that significant changes occurred between OCT scans and VF tests.<sup>64</sup> 501 Moreover, our sensitivity analysis utilizing only OCTs and VFs obtained on the same 502 day did not change our results, albeit it could be underpowered. 503 In conclusion, we developed a machine learning model to estimate MD from optic nerve 504 head OCT scans with a low prediction error compared to other structure-function 505 models in the literature. We used the model to estimate VFs from paired OCTs in 506 patients with longitudinal data. We found that even if OCT-MD is combined with VF-MD. 507 either through substitution or addition, it did not improve the ability to detect disease 508 progression compared to VF-MD alone. We conducted an error simulation analysis to 509 determine the accuracy needed for our model to detect glaucoma progression. We 510 found that when the MAE is 1 dB or better, OCT-MD could substitute VF-MD in trend-

511 based analysis. Future work developing structure-function models should aim to

- 512 achieve this lower level of prediction error to ensure the clinical utility of such models to
- 513 detect functional change over time.

## 514 References

- Zhang X, Dastiridou A, Francis BA, et al. Comparison of Glaucoma Progression
   Detection by Optical Coherence Tomography and Visual Field. *Am J Ophthalmol.* 2017;184:63-74. doi:10.1016/j.ajo.2017.09.020
- Zhang X, Loewen N, Tan O, et al. Predicting Development of Glaucomatous Visual
   Field Conversion Using Baseline Fourier-Domain Optical Coherence Tomography.
   *Am J Ophthalmol.* 2016;163:29-37. doi:10.1016/j.ajo.2015.11.029
- Kuang TM, Zhang C, Zangwill LM, Weinreb RN, Medeiros FA. Estimating Lead Time
   Gained by Optical Coherence Tomography in Detecting Glaucoma before
   Development of Visual Field Defects. *Ophthalmology*. 2015;122(10):2002-2009.
   doi:10.1016/j.ophtha.2015.06.015
- Wollstein G, Schuman JS, Price LL, et al. Optical coherence tomography
   longitudinal evaluation of retinal nerve fiber layer thickness in glaucoma. *Arch Ophthalmol Chic III 1960*. 2005;123(4):464-470. doi:10.1001/archopht.123.4.464
- 528 5. Hood DC, Kardon RH. A framework for comparing structural and functional
  529 measures of glaucomatous damage. *Prog Retin Eye Res.* 2007;26(6):688-710.
  530 doi:10.1016/j.preteyeres.2007.08.001
- Sung MS, Heo H, Park SW. Structure-function Relationship in Advanced Glaucoma
   After Reaching the RNFL Floor. *J Glaucoma*. 2019;28(11):1006-1011.
   doi:10.1097/IJG.0000000001374
- 534 7. Sommer A, Katz J, Quigley HA, et al. Clinically detectable nerve fiber atrophy
  535 precedes the onset of glaucomatous field loss. *Arch Ophthalmol Chic III 1960*.
  536 1991;109(1):77-83. doi:10.1001/archopht.1991.01080010079037
- 8. Hood DC. Improving our understanding, and detection, of glaucomatous damage:
  An approach based upon optical coherence tomography (OCT). *Prog Retin Eye Res.* 2017;57:46-75. doi:10.1016/j.preteyeres.2016.12.002
- 540
  9. Christopher M, Bowd C, Belghith A, et al. Deep Learning Approaches Predict
  541
  542
  543
  543
  544
  545
  545
  545
  546
  546
  547
  548
  549
  549
  549
  540
  540
  540
  541
  541
  541
  542
  542
  543
  543
  544
  544
  544
  544
  545
  545
  546
  546
  547
  547
  548
  549
  549
  549
  540
  540
  540
  541
  541
  541
  542
  542
  543
  544
  544
  544
  545
  545
  546
  547
  547
  548
  548
  549
  549
  549
  540
  540
  540
  540
  541
  541
  542
  542
  543
  543
  544
  544
  544
  545
  545
  546
  547
  547
  548
  548
  549
  549
  549
  540
  540
  541
  541
  542
  542
  543
  544
  544
  544
  544
  545
  545
  546
  546
  547
  547
  548
  548
  549
  549
  549
  540
  540
  540
  541
  541
  542
  542
  543
  544
  544
  544
  545
  545
  546
  546
  547
  547
  548
  548
  548
  549
  549
  549
  549
  540
  540
  541
  541
  542
  542
  542
  544
  544
  544
  544
  544
  544
  544
  544
  544
  544
  544
  544
- 544 10. Hashimoto Y, Asaoka R, Kiwaki T, et al. Deep learning model to predict visual field
  545 in central 10° from optical coherence tomography measurement in glaucoma. Br J
  546 Ophthalmol. 2021;105(4):507-513. doi:10.1136/bjophthalmol-2019-315600
- 547 11. Hemelings R, Elen B, Barbosa-Breda J, et al. Pointwise Visual Field Estimation
  548 From Optical Coherence Tomography in Glaucoma Using Deep Learning. *Transl Vis*549 *Sci Technol.* 2022;11(8):22. doi:10.1167/tvst.11.8.22

- 12. Mariottoni EB, Datta S, Dov D, et al. Artificial Intelligence Mapping of Structure to
   Function in Glaucoma. *Transl Vis Sci Technol*. 2020;9(2):19. doi:10.1167/tvst.9.2.19
- 552 13. Park K, Kim J, Lee J. A deep learning approach to predict visual field using optical
  553 coherence tomography. *PloS One*. 2020;15(7):e0234902.
  554 doi:10.1371/journal.pone.0234902
- 14. Tan O, Greenfield DS, Francis BA, Varma R, Schuman JS, Huang D. Estimating
  Visual Field Mean Deviation using Optical Coherence Tomographic Nerve Fiber
  Layer Measurements in Glaucoma Patients. *Sci Rep.* 2019;9(1):18528.
  doi:10.1038/s41598-019-54792-w
- 559 15. Zhu H, Crabb DP, Schlottmann PG, et al. Predicting visual function from the
  560 measurements of retinal nerve fiber layer structure. *Invest Ophthalmol Vis Sci.*561 2010;51(11):5657-5666. doi:10.1167/iovs.10-5239
- 562 16. Yu HH, Maetschke SR, Antony BJ, et al. Estimating Global Visual Field Indices in
  563 Glaucoma by Combining Macula and Optic Disc OCT Scans Using 3-Dimensional
  564 Convolutional Neural Networks. *Ophthalmol Glaucoma*. 2021;4(1):102-112.
  565 doi:10.1016/j.ogla.2020.07.002
- 17. Mwanza JC, Chang RT, Budenz DL, et al. Reproducibility of peripapillary retinal
  nerve fiber layer thickness and optic nerve head parameters measured with cirrus
  HD-OCT in glaucomatous eyes. *Invest Ophthalmol Vis Sci.* 2010;51(11):5724-5730.
  doi:10.1167/iovs.10-5222
- 570 18. Carpineto P, Nubile M, Agnifili L, et al. Reproducibility and repeatability of Cirrus<sup>™</sup>
  571 HD-OCT peripapillary retinal nerve fibre layer thickness measurements in young
  572 normal subjects. *Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd*.
  573 2012;227(3):139-145. doi:10.1159/000334967
- 574 19. Gürses-Ozden R, Teng C, Vessani R, Zafar S, Liebmann JM, Ritch R. Macular and
  575 retinal nerve fiber layer thickness measurement reproducibility using optical
  576 coherence tomography (OCT-3). *J Glaucoma*. 2004;13(3):238-244.
  577 doi:10.1097/00061198-200406000-00012
- 578 20. Garcia-Martin E, Pinilla I, Idoipe M, Fuertes I, Pueyo V. Intra and interoperator
  579 reproducibility of retinal nerve fibre and macular thickness measurements using
  580 Cirrus Fourier-domain OCT. *Acta Ophthalmol (Copenh)*. 2011;89(1):e23-e29.
  581 doi:10.1111/j.1755-3768.2010.02045.x
- 582 21. Tattersall CL, Vernon SA, Menon GJ. Mean deviation fluctuation in eyes with stable
   583 Humphrey 24-2 visual fields. *Eye*. 2007;21(3):362-366. doi:10.1038/sj.eye.6702206
- 22. Wall M, Doyle CK, Zamba KD, Artes P, Johnson CA. The repeatability of mean
  defect with size III and size V standard automated perimetry. *Invest Ophthalmol Vis Sci.* 2013;54(2):1345-1351. doi:10.1167/iovs.12-10299

- 587 23. Krakau CET. A statistical trap in the evaluation of visual field decay. *Acta* 588 *Ophthalmol (Copenh)*. 1985;63(S173):19-21. doi:10.1111/j.1755 589 3768.1985.tb06830.x
- 590 24. Nouri-Mahdavi K, Caprioli J, Coleman AL, Hoffman D, Gaasterland D. Pointwise
  591 Linear Regression for Evaluation of Visual Field Outcomes and Comparison With
  592 the Advanced Glaucoma Intervention Study Methods. *Arch Ophthalmol.*593 2005;123(2):193-199. doi:10.1001/archopht.123.2.193
- 594 25. Mwanza JC, Kim HY, Budenz DL, et al. Residual and Dynamic Range of Retinal
  595 Nerve Fiber Layer Thickness in Glaucoma: Comparison of Three OCT Platforms.
  596 Invest Ophthalmol Vis Sci. 2015;56(11):6344-6351. doi:10.1167/iovs.15-17248
- 597 26. Structure-function Relationship in Advanced Glaucoma After R...: Journal of 598 Glaucoma. Accessed December 15, 2022.
- https://journals.lww.com/glaucomajournal/Fulltext/2019/11000/Structure\_function\_R
   elationship\_in\_Advanced.10.aspx
- 601 27. Mwanza JC, Kim HY, Budenz DL, et al. Residual and Dynamic Range of Retinal
  602 Nerve Fiber Layer Thickness in Glaucoma: Comparison of Three OCT Platforms.
  603 *Invest Ophthalmol Vis Sci.* 2015;56(11):6344-6351. doi:10.1167/iovs.15-17248
- 804 28. Seibold LK, Mandava N, Kahook MY. Comparison of Retinal Nerve Fiber Layer
  805 Thickness in Normal Eyes Using Time-Domain and Spectral-Domain Optical
  806 Coherence Tomography. *Am J Ophthalmol.* 2010;150(6):807-814.e1.
  807 doi:10.1016/j.ajo.2010.06.024
- 29. Yohannan J, Wang J, Brown J, et al. Evidence-based Criteria for Assessment of
  Visual Field Reliability. *Ophthalmology*. 2017;124(11):1612-1620.
  doi:10.1016/j.ophtha.2017.04.035
- 30. De Moraes CGV, Juthani VJ, Liebmann JM, et al. Risk Factors for Visual Field
  Progression in Treated Glaucoma. *Arch Ophthalmol.* 2011;129(5):562-568.
  doi:10.1001/archophthalmol.2011.72
- 614 31. Chauhan BC, Garway-Heath DF, Goni FJ, et al. Practical recommendations for
  615 measuring rates of visual field change in glaucoma. *Br J Ophthalmol.*616 2008;92(4):569-573. doi:10.1136/bjo.2007.135012
- 617 32. Rabiolo A, Morales E, Mohamed L, et al. Comparison of Methods to Detect and
  618 Measure Glaucomatous Visual Field Progression. *Transl Vis Sci Technol.*619 2019;8(5):2. doi:10.1167/tvst.8.5.2
- 33. Hou K, Bradley C, Herbert P, et al. Predicting Visual Field Worsening with
  Longitudinal Optical Coherence Tomography Data Using a Gated Transformer
  Network. *Ophthalmology*. Published online March 30, 2023.
- 623 doi:10.1016/j.ophtha.2023.03.019

- 34. Guo Z, Kwon YH, Lee K, et al. Optical Coherence Tomography Analysis Based
  Prediction of Humphrey 24-2 Visual Field Thresholds in Patients With Glaucoma. *Invest Ophthalmol Vis Sci.* 2017;58(10):3975-3985. doi:10.1167/iovs.17-21832
- 35. Wong D, Chua J, Bujor I, et al. Comparison of machine learning approaches for
  structure–function modeling in glaucoma. *Ann N Y Acad Sci.* 2022;1515(1):237-248.
  doi:10.1111/nyas.14844
- 36. Yu HH, Maetschke SR, Antony BJ, et al. Estimating Global Visual Field Indices in
  Glaucoma by Combining Macula and Optic Disc OCT Scans Using 3-Dimensional
  Convolutional Neural Networks. *Ophthalmol Glaucoma*. 2021;4(1):102-112.
  doi:10.1016/j.ogla.2020.07.002
- 634 37. Lazaridis G, Montesano G, Afgeh SS, et al. Predicting Visual Fields From Optical
  635 Coherence Tomography via an Ensemble of Deep Representation Learners. *Am J*636 *Ophthalmol.* 2022;238:52-65. doi:10.1016/j.ajo.2021.12.020
- 637 38. Bogunović H, Kwon YH, Rashid A, et al. Relationships of Retinal Structure and
  638 Humphrey 24-2 Visual Field Thresholds in Patients With Glaucoma. *Invest*639 *Ophthalmol Vis Sci.* 2015;56(1):259-271. doi:10.1167/iovs.14-15885
- 39. Rabiolo A, Morales E, Afifi AA, Yu F, Nouri-Mahdavi K, Caprioli J. Quantification of
  Visual Field Variability in Glaucoma: Implications for Visual Field Prediction and
  Modeling. *Transl Vis Sci Technol.* 2019;8(5):25. doi:10.1167/tvst.8.5.25
- 40. Taketani Y, Murata H, Fujino Y, Mayama C, Asaoka R. How Many Visual Fields Are
  Required to Precisely Predict Future Test Results in Glaucoma Patients When
  Using Different Trend Analyses? *Invest Ophthalmol Vis Sci.* 2015;56(6):4076-4082.
  doi:10.1167/iovs.14-16341
- 647 41. Sehi M, Goharian I, Konduru R, et al. Retinal blood flow in glaucomatous eyes with
  648 single-hemifield damage. *Ophthalmology*. 2014;121(3):750-758.
  649 doi:10.1016/j.ophtha.2013.10.022
- 42. Yoshioka T, Song Y, Kawai M, et al. Retinal blood flow reduction in normal-tension
  glaucoma with single-hemifield damage by Doppler optical coherence tomography. *Br J Ophthalmol.* 2021;105(1):124-130. doi:10.1136/bjophthalmol-2019-315616
- 43. Kamalipour A, Moghimi S, Khosravi P, et al. Combining Optical Coherence
  Tomography and Optical Coherence Tomography Angiography Longitudinal Data
  for the Detection of Visual Field Progression in Glaucoma. *Am J Ophthalmol.*2023;246:141-154. doi:10.1016/j.ajo.2022.10.016
- 44. Wong D, Chua J, Tan B, et al. Combining OCT and OCTA for Focal Structure–
  Function Modeling in Early Primary Open-Angle Glaucoma. *Invest Ophthalmol Vis Sci.* 2021;62(15):8. doi:10.1167/iovs.62.15.8

- 45. Belghith A, Medeiros FA, Bowd C, et al. Structural Change Can Be Detected in
  Advanced-Glaucoma Eyes. *Invest Ophthalmol Vis Sci.* 2016;57(9):OCT511-518.
  doi:10.1167/iovs.15-18929
- 46. Bowd C, Zangwill LM, Weinreb RN, Medeiros FA, Belghith A. Estimating OCT
  Structural Measurement Floors to Improve Detection of Progression In Advanced
  Glaucoma. *Am J Ophthalmol.* 2017;175:37-44. doi:10.1016/j.ajo.2016.11.010
- 47. Lavinsky F, Wu M, Schuman JS, et al. Can Macula and Optic Nerve Head
  Parameters Detect Glaucoma Progression in Eyes with Advanced Circumpapillary
  Retinal Nerve Fiber Layer Damage? *Ophthalmology*. 2018;125(12):1907-1912.
  doi:10.1016/j.ophtha.2018.05.020
- 48. Drance SM. The early field defects in glaucoma. *Invest Ophthalmol.* 1969;8(1):84-91.
- 49. Nicholas SP, Werner EB. Location of early glaucomatous visual field defects. *Can J*673 *Ophthalmol J Can Ophtalmol.* 1980;15(3):131-133.
- 50. Anctil JL, Anderson DR. Early foveal involvement and generalized depression of the
  visual field in glaucoma. *Arch Ophthalmol Chic III 1960*. 1984;102(3):363-370.
  doi:10.1001/archopht.1984.01040030281019
- 51. Heijl A, Lundqvist L. The frequency distribution of earliest glaucomatous visual field
  defects documented by automatic perimetry. *Acta Ophthalmol (Copenh)*.
  1984;62(4):658-664. doi:10.1111/j.1755-3768.1984.tb03979.x
- 52. Schiefer U, Papageorgiou E, Sample PA, et al. Spatial pattern of glaucomatous
  visual field loss obtained with regionally condensed stimulus arrangements. *Invest Ophthalmol Vis Sci.* 2010;51(11):5685-5689. doi:10.1167/iovs.09-5067
- 53. Hood DC, Raza AS, de Moraes CGV, Liebmann JM, Ritch R. Glaucomatous
  damage of the macula. *Prog Retin Eye Res.* 2013;32C:1-21.
  doi:10.1016/j.preteyeres.2012.08.003
- 54. Arvanitaki V, Tsilimbaris MK, Pallikaris A, et al. Macular Retinal and Nerve Fiber
  Layer Thickness in Early Glaucoma: Clinical Correlations. *Middle East Afr J Ophthalmol.* 2012;19(2):204-210. doi:10.4103/0974-9233.95251
- 55. Xu L, Asaoka R, Kiwaki T, et al. Predicting the Glaucomatous Central 10-Degree
  Visual Field From Optical Coherence Tomography Using Deep Learning and Tensor
  Regression. *Am J Ophthalmol.* 2020;218:304-313. doi:10.1016/j.ajo.2020.04.037
- 56. Nouri-Mahdavi K, Mohammadzadeh V, Rabiolo A, Edalati K, Caprioli J, Yousefi S.
  Prediction of Visual Field Progression from OCT Structural Measures in Moderate to
  Advanced Glaucoma. *Am J Ophthalmol.* 2021;226:172-181.
- 695 doi:10.1016/j.ajo.2021.01.023

- 57. Medeiros FA, Zangwill LM, Alencar LM, et al. Detection of glaucoma progression
  with stratus OCT retinal nerve fiber layer, optic nerve head, and macular thickness
  measurements. *Invest Ophthalmol Vis Sci*. 2009;50(12):5741-5748.
  doi:10.1167/iovs.09-3715
- 58. Herbert P, Hou K, Bradley C, et al. Forecasting Risk of Future Rapid Glaucoma
  Worsening Using Early Visual Field, Optical Coherence Tomography, and Clinical
  Data. Ophthalmol Glaucoma. Published online March 19, 2023:S2589-
- 703 4196(23)00063-7. doi:10.1016/j.ogla.2023.03.005
- 59. Pham AT, Ramulu PY, Boland MV, Yohannan J. The Effect of Transitioning from
  SITA Standard to SITA Faster on Visual Field Performance. *Ophthalmology*.
  2021;128(10):1417-1425. doi:10.1016/j.ophtha.2021.03.032
- 60. Le CT, Fiksel J, Ramulu P, Yohannan J. Differences in visual field loss pattern when
  transitioning from SITA standard to SITA faster. *Sci Rep.* 2022;12(1):7001.
  doi:10.1038/s41598-022-11044-8
- 61. Heijl A, Patella VM, Chong LX, et al. A New SITA Perimetric Threshold Testing
  Algorithm: Construction and a Multicenter Clinical Study. *Am J Ophthalmol.*2019;198:154-165. doi:10.1016/j.ajo.2018.10.010
- 62. Mendieta N, Suárez J, Blasco C, Muñiz R, Pueyo C. A Comparative Study between
  Swedish Interactive Thresholding Algorithm Faster and Swedish Interactive
  Thresholding Algorithm Standard in Glaucoma Patients. *J Curr Ophthalmol.*2021;33(3):247-252. doi:10.4103/joco.joco\_148\_20
- 63. Phu J, Kalloniatis M. A Strategy for Seeding Point Error Assessment for Retesting
  (SPEAR) in Perimetry Applied to Normal Subjects, Glaucoma Suspects, and
  Patients With Glaucoma. *Am J Ophthalmol.* 2021;221:115-130.
  doi:10.1016/j.ajo.2020.07.047
- 64. Chauhan BC, Malik R, Shuba LM, Rafuse PE, Nicolela MT, Artes PH. Rates of
  Glaucomatous Visual Field Change in a Large Clinical Population. *Invest Ophthalmol Vis Sci.* 2014;55(7):4135-4143. doi:10.1167/iovs.14-14643
- 724

# 725 Tables and Figures:



726

Figure 1: (A) Various models were built using data obtained from OCT scans to

estimate a corresponding MD. (B) We then compared the ability to detect glaucoma

729 progression using OCT-MD estimates with VF-MD measurements to using only VF-MD

- alone. To establish a ground truth for both, eyes were labeled true progressors if the
- 731 MD slope calculated from all available VF studies (equating to at least 2 or more
- additional data points) was worse than -0.50 dB/year.



734 Figure 2: Mean absolute error of OCT-MD estimates across a range of VF-MD

733

<sup>735</sup> measurements



## 736

737 Figure 3: The predictive ability of VF-MD/OCT-MD slope calculated with different

percentages substitution for various MD-slope cutoff thresholds. Substitution of 0%

represents the performance of MD slopes calculated only from VF-MD (baseline VF-MD

slope). A substitution of 100% represents the performance of MD slopes calculated from

only OCT-MD. Dashed lines represent the performance of baseline VF-MD slopes using

742 20%, 40%, and 60% fewer VFs.



Error Simulation for VF-MD/OCT-MD

743

Figure 4: The predictive ability of VF-MD/OCT-MD slope with various levels of accuracy ranging from MAE of 0.50 to 1.50 dB. A substitution of 0% represents the performance

of MD slopes calculated only from VF-MD (baseline VF-MD slope). A substitution of

746 of MD slopes calculated only from VF-MD (baseline VF-MD slope). A substitution of 747 100% represents the performance of MD slopes calculated from only OCT-MD. Dashed

747 100% represents the performance of MD slopes calculated from only OCT-MD. Dashed

Ines represent the performance of baseline VF-MD slopes using 20%, 40%, and 60%

749 fewer VFs.

	Model dataset	Progression dataset
Mean age (SD), years	62 (15)	64 (11)
Gender		
Male, n	18,860 (42%)	1,715 (42%)
Female, n	25,794 (58%)	2,329 (58%)
Race		
White or Caucasian, n	24,413 (58%)	2,305 (57%)
Black or African American, n	13,068 (29%)	1,360 (34%)
Asian, n	3,220 (7.2%)	196 (4.9%)
American Indian or Alaska	150 (0.34%)	9 (0.22%)
Native, n		
Pacific Islander, n	48 (0.11%)	4 (0.10%)
Hispanic, n	2 (0.00%)	0 (0%)
Other, n	2,643 (5.9%)	125 (3.1%)
Unknown, n	1,115 (2.5%)	45 (1.1%)
Glaucoma Severity		
Suspect, n	15,000 (34%)	2,065 (51%)
Mild, n	25,984 (58%)	1,796 (44%)
Moderate, n	3,675 (8.2%)	183 (4.5%)
VF Characteristics		
Mean MD (SD), dB	-1.86 (2.54)	-1.59 (2.22)
Mean PSD (SD), dB	2.56 (1.89)	2.46 (1.72)
OCT Characteristics		
Mean RNFL (SD), µm	86 (12)	83 (11)
Mean CDR (SD)	0.60 (0.16)	0.62 (0.15)

# 750 Table 1: Baseline demographic, VF, OCT characteristics

\* SD = standard deviation, MD = mean deviation, PSD = pattern standard deviation,

RNFL = retinal nerve fiber thickness layer, CDR = cup-to-disc-ratio, VF = visual field,

753 OCT = optical coherence tomography

754

	Mean absolute error (dB)	% within 0.25 dB	% within 0.5 dB	% within 1 dB	% within 2 dB	% within 4 dB
Overall (n = 12,222)	1.62	11%	21%	41%	71%	93%
Suspect (n = 5,973)	1.36	12%	24%	44%	77%	98%
Mild (n = 5,337)	1.48	11%	21%	43%	72%	95%
Moderate (n = 912)	5.55	1.5 %	2.4%	3.9%	8.2%	21%

755	Table 2: OCT-MD Support V	ector Machine regre	ession performance metrics

756

\* OCT-MD = OCT derived mean deviation estimates; n = the number of OCT-VF pairs from each dataset 757